This article which was published in Fibromyalgia News Today on June 18th 2015 and written by Patricia Inacio, PhD discusses ‘an open-label pilot study’ – ‘The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study‘, which tried out an extended-release form of Gabapentin called G-GR (gastroretentive gabapentin)  for the treatment of Fibromyalgia.  However, as it is suggested in the article, although it gave some interesting results more in-depth research is required but the article instils a little hope for the development of medicines for Fibromyalgia 🙂

Opening Paragraph:

In a new study entitled “The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study” researchers showed that administration of the drug gabapentin (in an extended-release approach), initially prescribed as an anti-epilepsy medication, relieved fibromyalgia-associated pain symptoms and improved fibromyalgia patients’ quality of life. The study was published in the journal Pain Practice.

Read the rest of the article via: Novel Form of Extended-Release Gabapentin Improves Fibromyalgia Patients’ Pain Symptoms and Sleep Disorder Fibromyalgia News Today.